Meet Our Team: A collective of dedicated professionals committed to drive innovation and solve the painful oral side effects of radiotherapy and chemotherapy.
Board
Daniel Ehrenstråhle
Chairman of the board
Born in 1974, Daniel brings extensive experience as an executive, consultant, and advisor across various industries. Central to many of his roles is a broad scope of responsibilities covering strategy, transactions, M&A (buy and sell-side), portfolio management, governance, and go-to-market strategies in an international context. Prior to his 6 years in the executive group for global business units at Ericsson, Daniel worked 7 years at McKinsey and, before that, 3 years at ZS Associates in Paris, focusing on the pharmaceutical sector. Daniel Ehrenstråhle is independent in relation to both the Company and its management, as well as larger shareholders in the Company. Daniel Ehrenstråhle joined the board in 2023.
Marie-Louise Fjällskog
Board member, Chief Medical Officer
Marie-Louise Fjällskog is a qualified doctor and holds a PhD in medicine, with over 25 years’ experience in clinical oncology, translational research and global drug development. She currently serves as Chief Medical Officer at OncoZenge in Boston and holds board positions at Lytix Biopharma, Biovica International and Faron Pharmaceuticals. Marie has previously held senior positions at Sensei Biotherapeutics, Merus, Infinity Pharmaceuticals and the Novartis Institute for Biomedical Research, and has served as Chief Medical Officer at Faron Pharmaceuticals and Sensei Biotherapeutics.
Marie Moores
Board member
Marie Moores is a senior biopharmaceutical executive with nearly 30 years’ experience in oncology drug development and international operations. She has held senior positions at BioInvent International, Theradex Oncology and LINK Medical Research, where she has built up operations, strengthened regulatory capabilities and collaborated with global players in biotech and pharmaceuticals to drive next-generation cancer therapies. Marie has also served as a long-standing board member at Theradex Oncology and currently sits on the board of Aidee Health.
Paul Murtagh
Board member
Paul Murtagh has been a registered dentist in England, Ireland and Sweden since 2001. He trained at Trinity College Dublin and has received a research award in dentistry (IADR). Paul has founded and established several dental clinics in Ireland and one in Sweden and has served as a supervisor at Folktandvården and Sahlgrenska University Hospital in Gothenburg (the KUT programme). He has broad experience and expertise in oral health and dentistry, with a particular interest in research and business development within the sector.
Corporate
Stian Kildal
CEO
Stian Kildal has held several leadership positions with responsibility for P&L, product portfolios, and business development in an international setting. Most recently, he served as CEO of the Irish company Ammeon Ltd, which was sold to Intive GmbH following a structured exit process. Previous roles have included leadership in challenging restructuring situations as well as growth ambitions. Stian’s leadership is characterized by taking on challenges with a clear vision and strategy, building teams and structures to drive change, and executing towards set goals. Stian Kildal joined OncoZenge in 2023.
Marie-Louise Fjällskog
Chief Medical Officer (CMO)
Dr. Fjällskog is a board-certified oncologist and Associate Professor of Oncology (Docent) at Uppsala University, with extensive expertise in clinical development, regulatory strategy, and oncology drug development. She has held senior leadership roles in both academic and industry settings, with a proven track record in advancing oncology programs through clinical stages. Most recently, she has served as a senior clinical development consultant to OncoZenge, providing critical support to the Company’s BupiZenge™ Phase III program for the treatment of oral mucositis in cancer supportive care.
Michael Owens
Chief Financial Officer (CFO)
Michael Owens has over 20 years of experience in finance, with a focus on both large and small life science companies. His experience includes auditing at Arthur Andersen and being a Certified Auditor at EY, an active role in listing Karolinska Development, and financial and controller roles for several companies listed on NASDAQ First North. Previous roles have involved business development with divestments, acquisitions, financing, and asset listings. Michael joined OncoZenge in 2023.
Wenche Flovén
Economy & Admin
Marie Mannerlöf
Intellectual Property
Advisory Board
Stephen T. Sonis, DMD. DMSc
Professor of Oral Medicine, Harvard
Dr. Sonis is a senior academic at Harvard, Brigham and Women’s Hospital and the Dana-Farber Cancer Institute and a world-renowned expert on tissue toxicities of cancer therapy. His development of highly translational models has enabled the investigation of cancer regimen-related tissue toxicities and catalyzed development of potential therapies and innovative omics-based analytical approaches to clinically actionable outcomes to personalize therapy.
Dr. Sonis is the former President of Triad, an international not-for-profit company which focused on the adverse health and economic outcomes of cancer treatment toxicities and has served as a special employee of the FDA. He is a founder of Biomodels, a pre-clinical research organization, which was spun out of Brigham and Women’s Hospital in 1997 and has assisted in the development of drugs, devices, and biologicals for a wide range of indications including mucositis. A spin-off, Primary Endpoint Solutions (PES) assists companies throughout the clinical development process.
Dr. Sonis holds several patents and is the author of more than 300 original publications, reviews, and chapters and 11 books. He received his DMD from Tufts, completed his DMSc and residency at Harvard, and his postdoctoral training in tumor immunology at Oxford where he was a Knox Fellow.
Dr Pooja Nandwani Patel, MBBS, MD
Head of Department of Radiation Oncology, Sterling Cancer Hospital
Dr. Pooja Nandwani Patel is a Radiation Oncologist working in the field of cancer since 2005. Currently, she is a Senior Consultant and Head of the Radiation Oncology Department at Sterling Cancer Hospital, India. She is a very passionate Radiation Oncologist with patient care as the main focus in her daily practice.
She has received the Most Promising Young Oncologist Award from Indian Cancer Society in 2012. She has been the recipient of many popular fellowships from AROI (Association of Radiation Oncologists of India), ASTRO (American Society of Radiation, ESTRO (European Society for Radiotherapy & Oncology), IGCS (International Gynecological Cancer Society), SNO (Society of NeuroOncology) and ASCO (American Society of Clinical Oncology).
She has been trained at reputed international cancer centres abroad including Christie School of Oncology, NHS Foundation Trust, Manchester, England, Mannheim University, Mannheim, Germany, Newcastle upon Tyne Hospital, NHS Foundation Trust, England, United Kingdom, Kaiser Permanente Medical Hospital, Santa Clara, California, USA, Princess Margaret Hospital, Toronto, Canada, Long Beach Memorial Medical Centre, Long Beach, USA and The Methodist Hospital, Houston, USA
Her primary research interests involve head and neck malignancies, gynecological malignancies, breast cancer, prostate cancer and brain tumors. She is very keen to utilize her acquired knowledge through various international fellowships and trainings done abroad, into clinical practice for the betterment of her patients.
Dr Torben Mogensen, MD, PhD
Professor in AnesthesiologY, FMR Medical Director Hvidovre Hospital
Dr. Torben Mogensen is a distinguished Danish anesthesiologist and healthcare innovator, specializing in anesthesiology since 1991. He earned his Doctor of Medicine degree in 1995 and a Bachelor of Arts in Philosophy in 2012. His career began as a medical student inspired by a childhood appendicitis operation, evolving into a researcher focused on pain treatment.
He served as Medical Director at Hvidovre Hospital from 2003 to 2015, where he patented drugs for pain management. Post-retirement from that role, he has mentored life-science startups through the Nordic Mentor Network for Entrepreneurship (NOME), addressing innovation barriers in healthcare.
He has held positions as Professor at Lanzhou University, Gansu Province, since 2015. Dr. Mogensen is Chairman of the Danish Lung Association (Lungeforeningen) since 2019. With over 30 years in the sector, Dr. Mogensen has received accolades, including the 2018 Chinese Government Friendship Award for his contributions to medical collaboration.
Dr Paolo Bossi
Head of HEAD AND NECK CANCER UNIT, Humanitas Hospital, Milan
Paolo Bossi is a Medical Oncologist, Associate Professor and Head of the Head and Neck Cancer Unit at the Humanitas University and Humanitas Cancer Center in Milan, Italy.
He is involved in all institutional research activities on head and neck cancer, from translational research (gene expression, next generation sequencing) to assessment of quality of life and value-based medicine. He is particularly dedicated to rare cancer among head and neck cancers (paranasal sinus cancer, adnexal cancer, nasopharyngeal cancer, salivary gland cancer). He has strong experience with medical treatment of non-melanoma skin cancer, designing and conducting trials with targeted therapy and immunotherapy. He has a strong commitment to supportive care, specifically for what concerns mucositis induced by cancer therapies.
He collaborates with the Italian Network on Rare Tumors, a collaborative effort among Italian cancer centers, which tries to exploit distant patient sharing to improve quality of care and diminish health migration for rare solid cancers. He is the Principal Investigator and co-investigator of several Italian and International trials on Head and Neck cancer and non-melanoma skin cancer. Current responsibilities include; ESMO – Member of ESMO head and neck group and supportive and palliative care group, EORTC Head and Neck Group, Co-chair of the Older Adult Council at EORTC, MASCC – Chair of the Mucositis Study group for the period 2021-2024, AIOM (Italian Association of Medical Oncology), AIOCC (Italian Association of head and Neck Oncology), President of NICSO (Italian Network for Supportive Care in Oncology), Board of Director of GONO (Gruppo Oncologico Nord Ovest), Member of the SIOG Task Force on the Quality of Life in Older Cancer Patients and Member of the Head and Neck Cancer International Group Translational Research committee
